Table A1.
Characteristics of NSABP B-28 and B-14 Patients Included in the Current Study
| Variable | No. | % |
|---|---|---|
| NSABP B-28 ER+ patients (n = 1065) | ||
| Age, years | ||
| < 50 | 511 | 48.0 |
| ≥ 50 | 554 | 52.0 |
| Tumor size, cm | ||
| ≤ 2.0 | 483 | 45.4 |
| 2.1-4.0 | 467 | 43.8 |
| ≥ 4.1 | 115 | 10.8 |
| Positive nodes, No. | ||
| 1-3 | 722 | 67.8 |
| 4-9 | 300 | 28.2 |
| ≥ 10 | 43 | 4.0 |
| Central tumor grade | ||
| Well | 120 | 11.3 |
| Moderate | 499 | 46.9 |
| Poor | 405 | 38.0 |
| Unknown | 41 | 3.8 |
| Treatment | ||
| AC | 519 | 48.7 |
| AC→P | 546 | 51.3 |
| Surgery type | ||
| Lumpectomy | 461 | 43.3 |
| Mastectomy | 604 | 56.7 |
| NSABP B-14 tamoxifen-treated patients (n = 668) | ||
| Age, years | ||
| < 50 | 194 | 29.0 |
| ≥ 50 | 474 | 71.0 |
| Tumor size, cm | ||
| ≤ 2.0 | 414 | 62.0 |
| 2.1-4.0 | 220 | 32.9 |
| ≥ 4.1 | 34 | 5.0 |
| Central tumor grade | ||
| Well | 224 | 33.5 |
| Moderate | 296 | 44.3 |
| Poor | 148 | 22.2 |
Abbreviations: AC, doxorubicin plus cyclophosphamide, AC→P, doxorubicin plus cyclophosphamide followed by paclitaxel; ER, estrogen receptor; NSABP, National Surgical Adjuvant Breast and Bowel Project.